TY - JOUR
T1 - Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome
AU - Muñiz, Carmen
AU - Martín-Martín, Lourdes
AU - López, Antonio
AU - Sánchez-González, Blanca
AU - Salar, Antonio
AU - Almeida, Julia
AU - Sancho, Juan Manuel
AU - Ribera, José María
AU - Heras, Cecilia
AU - Peñalver, Francisco Javier
AU - Gómez, Marta
AU - González-Barca, Eva
AU - Alonso, Natalia
AU - Navarro, Belén
AU - Olave, Teresa
AU - Sala, Francisco
AU - Conde, Eulogio
AU - Márquez, José Antonio
AU - Cabezudo, Elena
AU - Cladera, Antonia
AU - García-Malo, María
AU - Caballero, María Dolores
AU - Orfao, Alberto
PY - 2014/3/20
Y1 - 2014/3/20
N2 - Flow cytometry (FCM) ismore sensitive than conventional cytology for detection of occult leptomeningeal lymphoma; however, some FCM-negative patients show central nervous system (CNS) recurrence. Here, we evaluated the cerebrospinal fluid (CSF) levels of 13 B-cell-associated markers and their contribution to the diagnosis of CNS lymphoma in 91 diffuse large B-cell lymphomas (DLBCL) and 22 Burkitt lymphomas (BLs). From all markers tested, CD19 wasthe most informative. Thus, higher soluble CD19 (sCD19) levels were associated with a greater frequency of neurological symptoms in DLBCL and BL and with parenchymal CNS lymphoma in DLBCL; sCD19 emerged as a powerful predictor of event-free and overall survival in DLBCL and BL, particularly when combined with FCM detection of CNS disease. These results support the utility of combined FCM detection of lymphoma cells and assessment of sCD19 levels in CSF, for more accurate identification of CNS disease in DLBCL and BL patients. © 2014 by The American Society of Hematology.
AB - Flow cytometry (FCM) ismore sensitive than conventional cytology for detection of occult leptomeningeal lymphoma; however, some FCM-negative patients show central nervous system (CNS) recurrence. Here, we evaluated the cerebrospinal fluid (CSF) levels of 13 B-cell-associated markers and their contribution to the diagnosis of CNS lymphoma in 91 diffuse large B-cell lymphomas (DLBCL) and 22 Burkitt lymphomas (BLs). From all markers tested, CD19 wasthe most informative. Thus, higher soluble CD19 (sCD19) levels were associated with a greater frequency of neurological symptoms in DLBCL and BL and with parenchymal CNS lymphoma in DLBCL; sCD19 emerged as a powerful predictor of event-free and overall survival in DLBCL and BL, particularly when combined with FCM detection of CNS disease. These results support the utility of combined FCM detection of lymphoma cells and assessment of sCD19 levels in CSF, for more accurate identification of CNS disease in DLBCL and BL patients. © 2014 by The American Society of Hematology.
UR - https://www.scopus.com/pages/publications/84897554800
U2 - 10.1182/blood-2013-11-537993
DO - 10.1182/blood-2013-11-537993
M3 - Article
SN - 0006-4971
VL - 123
SP - 1864
EP - 1869
JO - Blood
JF - Blood
IS - 12
ER -